Equities analysts predict that Dynavax Technologies Co. (NASDAQ:DVAX) will post earnings of $0.30 per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Dynavax Technologies’ earnings. The highest EPS estimate is $0.95 and the lowest is ($0.35). Dynavax Technologies posted earnings per share of ($0.56) in the same quarter last year, which would suggest a positive year-over-year growth rate of 153.6%. The company is expected to report its next quarterly earnings report on Monday, March 12th.
On average, analysts expect that Dynavax Technologies will report full-year earnings of ($1.36) per share for the current year, with EPS estimates ranging from ($1.75) to ($0.25). For the next year, analysts anticipate that the firm will report earnings of ($1.19) per share, with EPS estimates ranging from ($1.65) to ($0.59). Zacks’ EPS calculations are an average based on a survey of research firms that follow Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. During the same period in the previous year, the company earned ($0.90) earnings per share. The company’s revenue for the quarter was down 68.8% compared to the same quarter last year.
A number of analysts have recently issued reports on the company. BidaskClub lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. ValuEngine lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Cantor Fitzgerald boosted their price objective on Dynavax Technologies from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Thursday, November 9th. Cowen reissued a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a report on Friday, November 3rd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $28.00 price objective (up from $26.00) on shares of Dynavax Technologies in a report on Monday, September 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $25.17.
In related news, insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total value of $141,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.90% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Dynavax Technologies by 474.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 5,880 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in Dynavax Technologies by 54.5% in the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 3,700 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in Dynavax Technologies by 16.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 1,700 shares during the period. Legal & General Group Plc boosted its stake in Dynavax Technologies by 18.5% in the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 1,950 shares during the period. Finally, Wall Street Access Asset Management LLC acquired a new position in Dynavax Technologies in the second quarter valued at approximately $124,000. 70.54% of the stock is owned by hedge funds and other institutional investors.
Shares of Dynavax Technologies (DVAX) opened at $18.10 on Thursday. Dynavax Technologies has a 52-week low of $3.70 and a 52-week high of $24.45.
ILLEGAL ACTIVITY NOTICE: “Brokerages Expect Dynavax Technologies Co. (DVAX) to Announce $0.30 Earnings Per Share” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/12/21/brokerages-expect-dynavax-technologies-co-dvax-to-announce-0-30-earnings-per-share.html.
About Dynavax Technologies
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.